Story

Insulet Stock Tumbles After Company Cuts Full-Year Revenue Guidance

ENTHMSVIIDZHZH-TWJAKOHI
Aug 6, 20262 min read
Insulet Stock Tumbles After Company Cuts Full-Year Revenue Guidance
Text size
Background

Shares of Insulet Corporation (NASDAQ: PODD) plunged to a new 52-week low after the company significantly reduced its full-year revenue growth forecast, citing challenges with patient adoption and retention for its Omnipod insulin pump system. The updated outlook overshadowed a quarterly earnings beat and prompted a wave of downgrades from Wall Street analysts.

Guidance Cut Sparks Sell-Off

In its Q2 2026 earnings release, Insulet management lowered its full-year U.S. Omnipod growth forecast to a range of 17% to 19%, down from a prior estimate of 20% to 22%. The company also trimmed its guidance for total constant-currency revenue growth to 20% to 22%, from a previous range of 21% to 23%, while its Q3 revenue guidance also came in below analyst expectations.

According to CEO Ashley McEvoy, the revision was driven by lower-than-anticipated retention and utilization rates among new type 2 diabetes patients during their first 90 days. The company's updated guidance prudently assumes these trends will not improve during the second half of 2026.

Wall Street Downgrades

The revised forecast led to swift action from several investment banks, which added to the selling pressure on the stock. A number of analysts downgraded their ratings and slashed their price targets for Insulet.

Sample IUX Markets – In-articleAd
  • JPMorgan: Downgraded the stock to Neutral from Overweight and cut its price target to $152 from $275, citing expectations of decelerating sales growth through the rest of 2026 and into 2027.
  • Wells Fargo: Lowered its rating to Equal Weight from Overweight, slashing its price target to $144 from $255. Analysts noted that management now anticipates U.S. new patient starts will be flat to slightly down in 2027.
  • Oppenheimer: Downgraded PODD to Perform from Outperform, arguing the challenges in the type 2 diabetes market appear to be "structural rather than merely execution-related."

Market and Sector Impact

The combination of the guidance cut and analyst downgrades sent Insulet shares to a new 52-week low of $126.40. The negative sentiment also affected competitors in the diabetes device sector, with shares of Tandem Diabetes and DexCom also falling in sympathy.

The sell-off suggests investors are reassessing the growth trajectory and pace of market penetration for insulin pump technology in the broader type 2 diabetes population. An ongoing securities-fraud class-action lawsuit related to prior manufacturing issues was also cited as an overhang on investor sentiment.

Read next

More on Stocks
Back to latest news

LATEST